- Investing Ideas
- South Korean Pharmaceuticals & Biotech Healthy potentially undervalued
South Korean Pharmaceuticals & Biotech Healthy potentially undervalued
Results
8
Companies which are potentially undervalued and in an acceptable financial position.
8 companies
Hugel
Market Cap: ₩2.5t
Develops and manufactures biopharmaceuticals in South Korea and internationally.
A145020
₩236,000.00
7D
-12.6%
1Y
-33.1%
Dong-A Socio Holdings
Market Cap: ₩550.2b
Engages in the pharmaceutical business in South Korea.
A000640
₩83,000.00
7D
1.1%
1Y
-29.7%
Dong-A ST
Market Cap: ₩338.3b
Develops, manufactures, and markets pharmaceutical products in South Korea and internationally.
A170900
₩35,100.00
7D
0%
1Y
-26.1%
Daewoong Pharmaceutical
Market Cap: ₩1.5t
Develops, manufactures and commercializes pharmaceutical products in South Korea and internationally.
A069620
₩131,600.00
7D
5.7%
1Y
-19.0%
PharmaResearch
Market Cap: ₩3.2t
Operates as a biopharmaceutical company primarily in South Korea.
A214450
₩309,000.00
7D
-14.3%
1Y
-44.9%
Medy-Tox
Market Cap: ₩463.4b
Operates as a biopharmaceutical company in South Korea.
A086900
₩71,100.00
7D
-10.5%
1Y
-57.6%
Hanmi Pharm
Market Cap: ₩5.1t
A biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally.
A128940
₩401,000.00
7D
-8.0%
1Y
40.2%
ST PharmLtd
Market Cap: ₩2.5t
Provides manufacturing services for active pharmaceutical ingredient and intermediate.
A237690
₩119,200.00
7D
-8.1%
1Y
39.3%